Edition:
United Kingdom

VBI Vaccines Inc (VBIV.OQ)

VBIV.OQ on NASDAQ Stock Exchange Capital Market

4.19USD
4:41pm GMT
Change (% chg)

$0.09 (+2.20%)
Prev Close
$4.10
Open
$4.11
Day's High
$4.23
Day's Low
$4.11
Volume
42,716
Avg. Vol
53,438
52-wk High
$6.59
52-wk Low
$3.04

Latest Key Developments (Source: Significant Developments)

VBI Vaccines announces full exercise of option to purchase additional shares, upsized registered direct offering for proceeds of $71.9 mln
Monday, 30 Oct 2017 

Oct 30 (Reuters) - VBI Vaccines Inc -:VBI Vaccines announces full exercise of underwriters’ option to purchase additional shares and upsized registered direct offering for aggregate proceeds of $71.9 million.VBI Vaccines Inc - ‍in addition, VBI's previously announced concurrent registered direct offering was upsized from US$20.8 million to US$22.8 million​.  Full Article

VBI vaccines prices concurrent public offering and registered direct offering
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - VBI Vaccines Inc :VBI Vaccines prices concurrent public offering and registered direct offering for aggregate proceeds of $63.5 million.Vbi Vaccines Inc - ‍pricing of offering at a price to public of US$3.05 per share​.  Full Article

VBI Vaccines announces proposed concurrent public offering
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - VBI Vaccines Inc ::VBI Vaccines announces proposed concurrent public offering and registered direct offering of common shares.VBI Vaccines- to use proceeds from offerings to fund pivotal phase III clinical program for SCI-B-VAC in U.S., Europe, Canada​.VBI Vaccines Inc - ‍ to also use proceeds from offerings for funding phase I/IIA clinical study of VBI-1901 for glioblastoma multiforme, among others.  Full Article

VBI vaccines says Egidio Nascimento, has been named chief financial officer of company
Monday, 26 Sep 2016 

VBI Vaccines Inc :Says Egidio Nascimento, has been named chief financial officer of company.  Full Article

VBI Vaccines to continue Phase I Trial of its CMV Vaccine Candidate
Monday, 22 Aug 2016 

Vbi Vaccines Inc : Data safety monitoring board has no objection to co continuing enrollment in phase i clinical study to evaluate preventative cytomegalovirus vaccine candidate .Says will continue to share clinical trial safety data with Health Canada periodically throughout study.  Full Article

VBI Vaccines files for mixed shelf of upto $150 mln
Friday, 22 Jul 2016 

Vbi Vaccines Inc :VBI Vaccines Inc files for mixed shelf of upto $150 million - SEC filing.  Full Article

VBI Vaccines applies eVLP platform in development of vaccine candidate to prevent zika virus
Tuesday, 19 Jul 2016 

VBI Vaccines Inc : VBI Vaccines applies its EVLP platform in development of a novel vaccine candidate to prevent Zika virus .VBI is developing a bivalent Zika vaccine candidate consisting of e glycoprotein and ns1 glycoprotein.  Full Article

VBI Vaccines INC/BC says it has sold $13.6 million in equity financing
Tuesday, 5 Jul 2016 

Vbi Vaccines Inc : VBI Vaccines INC/BC says it has sold $13.6 million in equity financing - SEC Filing Source - http://bit.ly/29lId0Y Further company coverage: [VBIV.O] (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Arch Venture Fund reports 7.5 pct stake in VBI Vaccines as of May 6 - SEC filing
Monday, 27 Jun 2016 

Arch Venture Fund VI, L.P.:Arch Venture Fund VI, L.P. reports 7.5 pct stake in VBI Vaccines Inc as of May 6 - SEC filing.  Full Article

BRIEF-VBI Vaccines adds Ran Nussbaum to board

* Vbi vaccines strengthens board of directors with appointment of ran nussbaum Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)